Gladius Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs that selectively disrupt mitochondrial function in cancer cells by targeting the TRAP1 chaperone. This approach addresses the high metabolic demands of cancer cells, potentially offering novel treatment options while minimizing damage to healthy tissues.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer cells have high metabolic demands and often exist in nutrient-deprived, oxygen-starved environments, placing unique demands on their mitochondria. Current cancer therapies may not effectively target these mitochondrial vulnerabilities, potentially limiting treatment efficacy and causing damage to healthy tissues.
Solution
Gladius Therapeutics is developing small molecule drugs designed to selectively disrupt mitochondrial function in cancer cells by targeting the TRAP1 chaperone. Their lead candidate, Gamitrinib, is a first-in-class inhibitor of TRAP1, a HSP90 chaperone, that accumulates in the mitochondria. By targeting TRAP1, Gladius aims to address the high metabolic demands of cancer cells, potentially offering novel treatment options that minimize damage to healthy tissues. This approach exploits the cancer cell's reliance on mitochondrial function for survival and proliferation.
Target Audience
The primary target audience includes cancer patients with tumors that exhibit high metabolic demands and rely on mitochondrial function, as well as oncologists seeking novel therapeutic approaches.
Features
- Gamitrinib: A small molecule inhibitor of TRAP1, designed to accumulate in the mitochondria of cancer cells.
- Selective disruption of mitochondrial function in cancer cells.
- Targets the high metabolic demands specific to cancer cells.
- Aims to minimize damage to healthy tissues compared to traditional chemotherapy.
- Licensed patent portfolio covering mitochondria-targeted anti-tumor agents and combination therapies.